Cytokeratin7 antibody human specific - HS-454 008

Cytokeratin 7 is a type II keratin specifically expressed in the simple epithelia lining the cavities of the internal organs and in the gland ducts and blood vessels
Rabbit monoclonal recombinant IgG
Cat. No.: HS-454 008
Amount: 100 µl
Price: $415.00
Cat. No. HS-454 008 100 µl purified recombinant IgG, lyophilized. Albumin and azide were added for stabilization. For reconstitution add 100 µl H2O. Then aliquot and store at -20°C to -80°C until use.
Antibodies should be stored at +4°C when still lyophilized. Do not freeze!
Applications
 
WB: 1 : 1000 (AP-staining) gallery  
IP: not tested yet
ICC: 1 : 1000 gallery  
IHC: not tested yet
IHC-P: 1 : 200 up to 1 : 1000 gallery  
Clone Rb123E11
Subtype IgG1 (κ light chain)
Immunogen Synthetic peptide corresponding to residues surrounding AA 450 of human CK7 (UniProt Id: P08729)
Reactivity Reacts with: human (P08729).
No signal: mouse (Q9DCV7).
Other species not tested yet.
Remarks

This antibody is a chimeric antibody based on the monoclonal rat antibody clone 123E11H11. The constant regions of the heavy and light chains have been replaced by rabbit specific sequences. Therefore, the antibody can be used with standard anti-rabbit secondary reagents. The antibody has been expressed in mammalian cells.

Data sheet hs-454_008.pdf
Cat. No.: HS-454 008
Amount: 100 µl
Price: $415.00

Cytokeratin 7 staining in human invasive breast cancer

Background

Cytokeratins are cytoskeleton proteins of epithelial tissues, contributing to the mechanical stabilization of the cells. The cytokeratin family consists of at least 20 isotypes, which are largely specific for particular organs or tissue types. Therefore, immunohistochemical staining of cytokeratins is clinically used for diagnosis of carcinomas, in particular of unclear metastases and in precise classification and subtyping of tumors (1). Cytokeratin 7 (CK7) is expressed in healthy bladder, in the female genital tract epithelium, in mesothelium and in the lung (2). In tumors, CK7 expression is found in the majority of carcinoma types, with the exception of those carcinomas arising from the colon, prostate, kidney and thymus (3). Furthermore, CK7 expression can have prognostic relevance, e.g. adverse prognostic factor in lung cancer (4), or predictive relevance, e.g. predictive factor of response to concurrent radiochemotherapy in advanced cervical cancer (5).

Protocols for HS-454 008